Research analysts covering BIOXYTRAN.
Recent press releases and 8-K filings for BIXT.
Bioxytran Updates on Antiviral Drug Development and Oxygen Carrier Progress
BIXT
New Projects/Investments
Product Launch
- Bioxytran (BIXT) is developing a broad-range antiviral drug that targets galectin receptors on viruses, effective against COVID-19, influenza, shingles, long COVID, conjunctivitis, and RSV.
- A double-blind placebo-controlled Phase II clinical trial for COVID-19 demonstrated 88% of patients had no detected virus by day three and no detection by day seven, significantly faster than Paxlovid's reported efficacy.
- A second confirmatory Phase II trial for dose response is currently undergoing data analysis, with results anticipated soon. The company plans to pursue Phase III trials for a medical claim, potentially through partnerships, targeting an estimated $80 billion antiviral market.
- Bioxytran is also advancing BXT-25, a universal oxygen carrier derived from camel hemoglobin, for early stroke treatment, which is entering clinical trials.
4 hours ago
BioXyTran Presents Promising Antiviral Phase 2 Results and Stroke Treatment Development
BIXT
Product Launch
New Projects/Investments
Guidance Update
- BioXyTran (BIXT) is developing a broad-range antiviral drug that blocks galectin receptors on viruses. A Phase 2 clinical trial for COVID-19 demonstrated 88% of patients had no detectable virus by day 3 and 100% by day 7, with no adverse effects.
- A second Phase 2 study for dose response of the antiviral is currently being analyzed, with results expected soon. The company aims to commercialize the antiviral as a nutraceutical while pursuing Phase 3 trials with a partner for specific medical claims.
- The company is also developing BXT-25, a universal oxygen carrier for early stroke treatment, which is 5,000 times smaller than red blood cells and stable for years at room temperature. Toxicity testing is nearing completion, and clinical trials will commence once funding is available.
- BioXyTran was formed in 2017, has 37 million shares in float, and is currently valued between $5 and $7. The estimated total antiviral market is approximately $80 billion.
4 hours ago
BioXyTran provides updates on broad-range antiviral and oxygen carrier development
BIXT
New Projects/Investments
Revenue Acceleration/Inflection
- BioXyTran (BIXT) has completed a Phase 2 double-blind placebo-controlled clinical trial for a broad-range antiviral drug, demonstrating that 88% of COVID-19 patients had no detected virus by day 3 and 100% by day 7.
- A second confirmatory Phase 2 trial for the antiviral, which also evaluates dose response, is currently being analyzed, with data expected "very soon".
- The company is also developing BXT-25, a universal oxygen carrier for early stroke treatment, which is entering clinical trials after toxicity testing.
- BIXT was formed in 2017, has 37 million shares in the float, and is currently valued between 5 and 7.
5 hours ago
Bioxytran Provides Update on Clinical Programs and Partnership Strategy
BIXT
New Projects/Investments
Guidance Update
- Bioxytran (BIXT), a clinical-stage biotech, is developing three platform technologies: broad-spectrum antivirals, an oxygenation molecule for stroke treatment, and a cancer metastasis drug.
- Its broad-spectrum oral antiviral, ProLectin-M, recently completed clinical trials, demonstrating 100% viral reduction in seven days, with a top-line data readout expected before year-end 2025.
- The company is actively seeking a collaboration partner for its antiviral for an FDA trial and plans to present its cancer metastasis platform at the upcoming J.P. Morgan Conference to explore partnerships for boosting immunotherapy response rates.
- Bioxytran's oxygenation molecule for stroke is designed to provide an "oxygen bridge" to reduce brain damage, targeting a market potentially larger than the existing $6 billion-$7 billion annual tPA market.
Dec 11, 2025, 7:55 PM
Bioxytran Provides Corporate Update on Clinical Trials and Partnership Strategy
BIXT
New Projects/Investments
Guidance Update
- Bioxytran (BIXT) is a clinical-stage biotech company focused on three platform technologies: broad-spectrum antivirals, an oxygenation molecule for stroke, and a cancer metastasis drug.
- The company's broad-spectrum antiviral, ProLectin-M, recently completed a dose escalation trial, with top-line data expected before year-end (2025). The contract research organization (CRO) indicated positive data, suggesting a potential for a Phase 3 application.
- Bioxytran plans to optimize its Phase 3 trial design for the Indian market and conduct an all-comers trial for upper respiratory tract infections, including influenza, RSV, and COVID-19.
- The company is actively seeking collaboration partners, particularly for its antiviral after the data readout, and will showcase its cancer metastasis platform at the J.P. Morgan Conference to discuss combination therapies.
Dec 11, 2025, 7:55 PM
Bioxytran Provides Update on Clinical Trials, Partnership Efforts, and Pipeline Development
BIXT
New Projects/Investments
Guidance Update
M&A
- Bioxytran (BIXT) has completed enrollment for its dose escalation trial of a broad-spectrum oral antiviral drug and anticipates a top-line data readout before year-end 2025. The company's CRO has indicated positive data, expecting a Phase 3 application soon.
- The planned Phase 3 trial for the antiviral will be optimized for the Indian market and designed as an "all-comers" trial to treat upper respiratory tract infections, including influenza, RSV, and COVID-19.
- The company is actively seeking a collaboration partner for its broad-spectrum antiviral for an FDA trial and plans to showcase its cancer metastasis platform at the upcoming J.P. Morgan Conference to explore combination therapies with immunotherapy drugs.
- Bioxytran is developing an oxygenation molecule as a stroke drug, which aims to reduce brain damage by providing an oxygen bridge, targeting a market potentially larger than the existing $6 billion-$7 billion annual tPA market.
Dec 11, 2025, 7:55 PM
BIOXYTRAN Announces Initiation of Stock Coverage by Independent Research
BIXT
New Projects/Investments
- BIOXYTRAN (BIXT) announced on November 13, 2025, that Independent Research, a global equity research firm specializing in micro-cap and small-cap public companies, has initiated coverage of its stock.
- The research highlights the company's lead candidate, ProLectin-M, which demonstrated rapid viral clearance in COVID-19 patients, and BXT-25, an ambulatory stroke treatment aiming to significantly reduce treatment time and capture a majority share of the multibillion-dollar global stroke market.
- The report notes over 50% insider ownership and minimal cash compensation, underscoring management's commitment to shareholder value.
- While considered a speculative investment, the primary risk identified is funding, as the company has struggled to raise capital and has relied heavily on insider support.
Nov 13, 2025, 6:50 PM
Bioxytran Completes Randomized Clinical Trial
BIXT
New Projects/Investments
- BIOXYTRAN, INC. has successfully completed its second randomized double-blind, placebo-controlled clinical trial for its leading broad-spectrum antiviral drug candidate, ProLectin-M.
- This trial was designed to confirm previous Phase 2 study results, which showed ProLectin-M achieved undetectable levels of Polymerase Chain Reaction (PCR) and infection in less than one week in treated participants.
- The data from this completed trial is expected to inform the CDSCO for a Phase 3 trial design and will also be submitted to the FDA.
- ProLectin-M is positioned as the first oral antiviral sugar chemistry drug.
Oct 29, 2025, 1:30 PM
Fintool News
In-depth analysis and coverage of BIOXYTRAN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more